人血浆蛋白质组学分析揭示磷酸丙糖异构酶作为类风湿关节炎甲氨蝶呤耐药潜在血液标志物
本研究比较了稳定接受皮下甲氨蝶呤治疗至少3个月的类风湿关节炎患者中,缓解组(DAS28<2.6,n=24)与活动组(DAS28>3.2,n=32)的血浆蛋白差异表达。非靶向蛋白质组学发现8种差异表达蛋白,其中糖酵解关键酶磷酸丙糖异构酶(TPI-1)和葡萄糖-6-磷酸异构酶(GPI)在活动组下调,靶向分析证实了TPI-1的结果。作者认为这是寻找甲氨蝶呤耐药生物标志物的第一步,下一步需在更大队列(含未治疗患者样本)中验证。
要点
- 非靶向蛋白质组学发现活动组与缓解组间有8种血浆蛋白差异表达。
- 糖酵解关键酶TPI-1和GPI在活动组下调,靶向分析证实TPI-1下调。
- 作者认为这是寻找甲氨蝶呤耐药标志物的第一步,需在更大队列中验证。
核心结论
- 在寻找甲氨蝶呤耐药生物标志物方面迈出了第一步,鉴定出糖酵解中的两个参与者TPI-1和GPI。
- 下一步将在更大队列中确认这些结果,包括来自未治疗患者的样本,以评估这些蛋白标志物的预测潜力。
研究设计与样本
- 纳入接受稳定剂量皮下甲氨蝶呤治疗至少3个月的类风湿关节炎患者,按DAS28分为缓解组(DAS28<2.6;n=24)和活动组(DAS28>3.2;n=32)。
- 两组患者流行病学特征均一,但缓解组治疗持续时间更长。
- 采集血样后进行血浆蛋白消化,随后进行非靶向蛋白质组学分析,再进行靶向分析以确认非靶向方法的结果。
主要发现
- 非靶向蛋白质组学分析显示两组患者之间有8种血浆蛋白差异表达。
- 糖酵解主要参与者磷酸丙糖异构酶(TPI-1)和葡萄糖-6-磷酸异构酶(GPI)在活动组下调。
- 靶向蛋白质组学分析证实了TPI-1在活动组下调的结果。
局限性
- 两组患者流行病学特征均一,但缓解组治疗持续时间更长。
- 作者指出下一步需在更大队列中确认结果,包括来自未治疗患者的样本,以评估这些蛋白标志物的预测潜力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study was to assess differentially expressed blood proteins between patients with active RA and patients in remission after MTX treatment, with the aim of identifying a biomarker of MTX resistance (MTXR). METHODS: Two populations of RA patients treated with a stable dose of s.c. MTX for at least 3 months were constituted according to the DAS28: remission (DAS28 < 2.6; n = 24) and active disease (DAS28 > 3.2; n = 32). The two groups of RA patients were homogeneous regarding their epidemiological characteristics, except for the duration of treatment, which was longer in the remission group. After collection of a blood sample, plasma protein digestion was performed, followed by untargeted proteomics analysis. Then, a targeted analysis was performed to confirm the results of the untargeted approach. RESULTS: Untargeted proteomics analysis revealed eight plasma proteins that were differentially expressed between the two groups of patients. Among them, triosephosphate isomerase (TPI-1) and glucose-6-phosphate isomerase (GPI), which are main actors in glycolysis, were found down-regulated in the active group. This result was confirmed for TPI-1 in the targeted proteomics analysis. CONCLUSION: A first step was achieved in the search for biomarkers of MTXR, with the identification of two actors in glycolysis (TPI-1 and GPI). The next step will be to confirm these results in a larger cohort, including samples from treatment-naive patients, to assess the predictive potential of these protein markers.
引用
- Escal J, Neel T, Hodin S, et al. Proteomics analyses of human plasma reveal triosephosphate isomerase as a potential blood marker of methotrexate resistance in rheumatoid arthritis. Rheumatology (Oxford). 2024. PMID: 37527020. doi:10.1093/rheumatology/kead390
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。